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AntimicrobialAbstract A series of 1,3,4-thiadiazole derivatives of 2-(4-formyl-2-methoxyphenoxy) acetic acid
(6a–s) were synthesized by cyclization of carboxylic acid group of 2-(2-methoxy-4-(3-oxo-3-substi-
tuted phenylprop-1-enyl)phenoxy) acetic acid (4a–s) with thiosemicarbazide in the presence of
POCl3 or PPA. The structures of the compounds were conﬁrmed by IR,
1H NMR and mass anal-
ysis. All the compounds have been evaluated in vitro for their antimicrobial activities against several
strains of microbes and show signiﬁcant activity.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The treatment of infectious disease caused by bacteria, fungi
and viruses still remains an important and challenging problem
because of a combination factors including newly emerginginfectious diseases and increasing number of multi-drug resis-
tant gram-positive pathogens (Tenover and McDonald, 2005;
Pfeltz and Wilkinson, 2004; Roberts, 2004; Dessen et al.,
2001), such as methicillin-resistant Staphylococcus aureus
(MRSA), penicillin resistant Streptococcus pneumoniae
(PRSP), and vancomycin-resistant Enterrococci (VRE), com-
pounded problems in the therapeutics (Babu et al., 2008;
Dalhoff, 1994). Thus it is still necessary to search for new
antimicrobial agents.
Five membered aromatic systems having three hetero atoms
at symmetrical position have interesting physiological proper-
ties (Hetzhein and Mockel, 1996; Sandstrom, 1968). During re-
cent years there has been intense investigation of different
classes of thiadiazole compounds, many of which known to
Scheme 1 Reagents: (a) chloroacetic acid, NaOH, HCl; (b) EtOH, KOH, petroleum ether; (c) thiosemicarbazide, glacial acetic acid; (d)
thiosemicarbazide, PPA or POCl3.
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(Demirbas et al., 2009; Kadi et al., 2007; Bekhit and Abdel-
Aziem, 2004), anti-inﬂammatory (Mullican et al., 1993; Song
et al., 1999; Mathew et al., 2007), anticonvulsants (Chapleo
et al.,1986, 1988), antioxidant (Cressier et al., 2009), anticancer
(Matysiak et al., 2006; Chou et al., 2003; Radi et al., 2008) and
antifungal (Swamy et al., 2006) activities. The activity of 1,3,4-
thiadiazoles is possibly due to the presence of the ‚N–C–S
moiety (Bauer et al., 1966). In view of these facts, we have syn-
thesized several new 1,3,4-thiadiazole derivatives of 2-(4-for-
myl-2-methoxyphenoxy) acetic acid moiety in order to study
their biodynamic behavior. The present study reports the syn-
thesis of 3-(4-((5-amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(substituted)-4,5-dihydro-1H-pyrazole-1
carbothioamide (6a–s) by appropriate methods and their eval-
uation for antibacterial and antifungal potentials.
2. Chemistry
The synthetic route of compounds (6a–s) is shown in Scheme
1. 2-(4-Formyl-2-methoxyphenoxy) acetic acid (2) was pre-pared by reacting vanillin with chloroacetic acid in the pres-
ence of sodium hydroxide. Various chalcone derivatives
(4a–s) were synthesized by treating (2) with different deriva-
tives of acetophenone (3a–s). Compounds (5a–s) were ob-
tained by reﬂuxing (4a–k) and thiosemicarbazide in the
presence of glacial acetic acid and ethanol. 1,3,4-Thiadiazole
derivatives (6a–s) were obtained by cyclization of (5a–s) by
treating with thiosemicarbazide and POCl3 or PPA. The phys-
ical data of all the synthesized compounds is shown in Table 1.
3. Biological activity
All the synthesized 1,3,4-thiadiazole derivatives (6a–s) have
been screened for both antibacterial and antifungal activities
using cup-plate agar diffusion method by measuring zone of
inhibition in mm. Eight different bacterial cultures S. aureus,
Salmonella enterica, Vibrio cholera, Bacillus subtilis, Proteus
mirabili, Escherichia coli V517, Mycobacterium smegmatics,
Pseudomonas aeruginosa in nutrient agar medium, and one
fungal culture Candida albicans in sabouraud’s dextrose agar
medium (Holla et al., 2002) were used. The results were com-
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(50 lg/ml) for bacteria and amphotericin B (50 lg/ml) for fun-
gi and negative control, the DMSO poured disk. These steril-
ized agar media were poured into petri-dishes and allowed to
solidify. On the surface of the media microbial suspensions
were spread with the help of sterilized triangular loop. A stain-
less steel cylinder of 8 mm diameter (pre-sterilized) was used to
bore cavities. All the synthesized compounds (50 lg/ml) were
placed serially in the cavities with the help of micropipette
and allowed to diffuse for 1.0 h. DMSO was used as a solvent
for all the compounds, and as a control. These plates were
incubated at 37 C for 24 h and 28 C for 48 h, for the antibac-
terial and antifungal activities, respectively. The zone of inhibi-
tion was observed around the cup after respective incubation
and was measured and percent inhibition of the compounds
was calculated.
4. Results and discussion
The structures of synthesized compounds were established on
the basis of their spectral data. Spectral data of compounds
were in full agreement with proposed structures. The forma-
tion of 1,3,4-thiadiazoles (6a–s) was supported by the presence
of N–H band in the IR spectra and absence of carbonyl
stretching band of the carboxylic acid function. In general, in-
fra red spectra (IR) revealed a bilobe of NH2 stretch at 3100,
3300, and C‚N, C–N and C‚S peak at 1530, 1328, and
1126 cm1, respectively. In the nuclear magnetic resonance
spectra (1H NMR) the signals of the respective protons of
the prepared titled compounds were veriﬁed on the basis of
their chemical shifts, multiplicities, and coupling constants.
The spectra showed a singlet at d 5.2 ppm corresponding
to OCH2 group; doublet at d 4.0 ppm corresponding to C4
methylene group; singlet at d 3.8 ppm corresponding to
methoxy group; singlet at d 3.2 ppm corresponding to C5
CH group; singlet at d 5.8 ppm corresponding to NH2 andTable 1 Physical property data of compounds (6a–s).
Compound R Molecular form
6a H C20H20N6O2S2
6b 2-OCH3 C21H22N6O3S2
6c 2,4-di-Cl C20H18Cl2N6O2
6d 3-NH2 C20H21N7O2S2
6e 3-NO2 C20H19N7O4S2
6f 4-OCH3 C21H22N6O3S2
6g 4-F C20H19FN6O2S2
6h 4-NO2 C20H19N7O4S2
6i 4-Br C20H19BrN6O2S
6j 4-CH3 C21H22N6O2S2
6k 3-OH C20H20N6O3S2
6l 2-OH C20H20N6O3S2
6m 4-Cl C20H19ClN6O2S
6n 2-NH2 C20H21N7O2S2
6o 2,4-diOH C20H20N6O4S2
6p 4-NH2 C20H21N7O2S2
6q 2-Cl C20H19ClN6O2S
6r 4-OH C20H20N6O3S2
6s 3-CH3 C21H22N6O2S2multiplet at d 6.5–8.2 ppm for aromatic proton; singlet at d
8.5 ppm corresponding to another NH2 group.
The 1,3,4-thiadiazole derivative 6h showed activity
against all the strains. It showed maximum activity (97%)
against S. enterica (95%), against V. cholera and (87.9%)
inhibition of E. coli V517 when compared with standard
drug ampicillin. Compound 6e showed (93.2% and 89.5%
inhibition) against S. enterica and V. cholera, respectively.
Compound 6k showed maximum inhibition (87.1%) against
S. aureus. Compound 6o was found to be active (96.5%
inhibition) against E. coli V517 and 6p showed (90.2% inhi-
bition) against P. aeruginosa. Rest of all the 1,3,4-thiadiazole
derivatives showed moderate to good antibacterial
activity. The 1,3,4-thiadiazole derivative 6h showed maxi-
mum inhibition (87.8%) whereas, compound 6e showed
(83.3%) inhibition against fungal strain C. albicans. Rest
of all the 1,3,4-thiadiazole derivatives showed moderate to
low antifungal activity. The results are presented in Table 2.
5. Experimental
Chemicals were purchased from Merck India, Spectrochem
and Sigma–Aldrich etc. Most of the solvents and chemicals
used were of LR grade. The purity of the compounds was con-
ﬁrmed by thin layer chromatography using precoated TLC
plates and solvent systems of benzene–acetone (9:1), (8:2); T–
E–F (5:4:1), and chloroform–methanol (9:1), (9.5:0.5). The
spots were visualized under ultraviolet lamp. Melting points
were determined in one end open capillary tubes on a liquid
parafﬁn bath and are uncorrected. Infrared (IR) and 1H nucle-
ar magnetic resonance (1H NMR) spectra were recorded for
the compounds on Perkin Elmer IR (mmax in cm
1) spectropho-
tometer in KBr pellets and Bruker model avance II (400 MHz,
1H NMR) instrument, respectively. Chemical shifts are re-
ported in parts per million (ppm) using tetramethylsilane
(TMS) as an internal standard.ula Yield (%) Melting point (C)
42 262–267
44 274–278
S2 36 232–238
26 252–256
36 298–303
42 268–272
20 244–247
44 302–306
2 66 274–279
62 282–286
66 312–317
68 258–262
2 65 228–232
59 264–268
67 306–310
70 222–226
2 65 254–258
69 288–292
64 272–276
Table 2 Antimicrobial activity data for compounds (6a–s).
Compound % Inhibition
S. aureus S. enterica V. cholera B. subtilis P. mirabilis E. coli V517 M. smegmatics P. aeruginosa C. albicans
6a – – – 49.6 – 62.9 33.7 44.7 –
6b – 76.8 38.2 54.7 66.6 77.0 63.9 69.4 –
6c 75 85.0 78.3 – 66.6 82.7 – – 70.5
6d – 68.6 – 59.8 – – 58.1 62.6 48.0
6e 78.5 93.2 89.5 77.3 80.0 84.4 75.5 74.6 83.3
6f – 78.3 44.4 59.8 70.0 80.1 67.4 74.6 –
6g 75.7 76.8 83.3 80.2 77.3 87.9 72.0 83.5 77.5
6h 80.7 97.0 95.0 81.7 87.3 8.9 81.3 82.8 87.8
6i – 69.4 52.4 49.6 46.6 62.9 – – 53.8
6j – 73.1 46.9 59.1 52.0 79.3 58.1 58.2 –
6k 87.1 79.8 – – – 64.6 – – 55.1
6l 77.1 73.8 – – 59.3 75.8 – – 62.8
6m 80.0 79.1 71.4 – 58 85.3 80.2 73.1 72.4
6n – 70.8 – 67.8 – 88.7 70.3 75.3 62.8
6o 84.2 76.8 – 78.8 70.6 96.5 79.6 86.5 66
6p – 86.5 – 82.4 – 83.6 83.1 90.2 51.2
6q 81.4 85.8 79 70 66 73.2 74.4 60.4 69.8
6r 76.4 81.3 – 85.4 – – 65.6 55.9 63.4
6s – 70.8 54.9 70.8 52 75 73.2 81.3 –
Stand. 100 100 100 100 100 100 100 100 100
(–): No zone of inhibition.
Std.: Standard (ampicillin for bacteria and amphotericin B for fungi).
S1286 M.N. Noolvi et al.5.1. Synthesis of 2-(4-formyl-2-methoxyphenoxy) acetic acid
(2)
Compound (2) was prepared by the procedure given in the lit-
erature (Zubrys and Stebenmann, 1954).
5.2. Synthesis of 2-{4-[3-(substituted)-3-oxo-1-propenyl]-2-
methoxyphenoxy} acetic acid (4a–k) and 2-{4-[1-amino
(thioxo) methyl-5-(substituted phenyl)-4,5-dihydro-1H-3-
pyrazolyl]-2-methoxyphenoxy} acetic acid (5a–k)
Compounds (4a–k) and (5a–k) were prepared by the procedure
given in the literature (Mohammad and Mohammad, 2007).
5.3. General procedure for the synthesis of 3-(4-((5-amino-
1,3,4-thiadiazol-2-yl)methoxy)-3-methoxyphenyl)-5-(substitu
ted)-4,5-dihydro-1H-pyrazole-1-carbothioamide (6a–k)
A mixture of (5a–k) (0.05 mol), thiosemicarbazide (0.05 mol)
and POCl3 (13 ml) was heated at 75 C for 0.75 h. After cool-
ing down to room temperature, water was added. The reaction
mixture was reﬂuxed for 4 h. After cooling, the mixture was
basiﬁed to pH 8 by the drop-wise addition of 50% NaOH solu-
tion under stirring. The precipitate was ﬁltered and recrystal-
lized from ethanol.
5.3.1. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-
carbothioamide (6a)
Yield 42%; mp: 262–267 C; IR (KBr, cm1): 3327.40, 3290.63
(N–H stretch), 3010.29 (Ar C–H stretch), 2919.01 (C–H
stretch), 1570.29 (Ar C‚C stretch); 1H NMR (DMSO-d6):
9.19 (s, 2H, NH2), 6.72–7.94 (m, 8H, Ar-H), 5.48 (s, 2H,NH2), 5.12 (s, 2H, OCH2), 4.00 (d, 2H, CH2), 3.84 (s, 3H,
OCH3), 3.41 (s, 1H, CH), MS (m/z %): 441.08 [M+1]
+.5.3.2. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(2-methoxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carbothioamide (6b)
Yield 44%; mp: 274–278 C; IR (KBr, cm1): 3157.02, 3111.20
(N–H stretch), 3041.76 (Ar C–H stretch), 2986.18 (C–H
stretch), 1570.41 (Ar C‚C stretch); 1H NMR (DMSO-d6):
9.26 (s, 2H, NH2), 7.26–8.26 (m, 7H, Ar-H), 5.78 (s, 2H,
NH2), 5.20 (s, 2H, OCH2), 4.23 (d, 2H, CH2), 3.82 (s, 6H,
OCH3), 3.53 (s, 1H, CH); MS (m/z %): 471.18 [M+1]
+.5.3.3. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(2,4-dichlorophenyl)-4,5-dihydro-1H-
pyrazole-1-carbothioamide (6c)
Yield 36%; mp: 232–238 C; IR (KBr, cm1): 3349.34, 3329.20
(N–H stretch), 3086.49 (ArC–H stretch), 2998.26 (C–H stretch),
1559.31 (Ar C‚C stretch), 1H NMR (DMSO-d6): 8.92 (s, 2H,
NH2), 6.75–7.98 (m, 6H, Ar-H), 5.89 (s, 2H, NH2), 5.29 (s,
2H, OCH2), 4.24 (d, 2H, CH2), 3.83 (s, 3H, OCH3), 3.63 (s,
1H, CH); MS (m/z%): 508. 09 [M+], 509.11 [M+1]+.
5.3.4. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(3-aminophenyl)-4,5-dihydro-1H-pyrazole-
1-carbothioamide (6d)
Yield 26%; mp: 252–256 C; IR (KBr, cm1): 3263.24, 3230.38
(N–H stretch), 3018.76 (Ar C–H stretch), 2986.18 (C–H
stretch), 1598.83 (Ar C‚C stretch); 1H NMR (DMSO-d6):
12.6 (s, 2H, NH2), 10.1 (s, 2H, NH2), 6.72–8.44 (m, 7H, Ar-
H), 5.38 (s, 2H, NH2), 5.15 (s, 2H, OCH2), 4.15 (d, 2H,
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455.15 [M+].
5.3.5. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(3-nitrophenyl)-4,5-dihydro-1H-pyrazole-1-
carbothioamide (6e)
Yield 36%; mp: 298–303 C; IR (KBr, cm1): 3129.46, 3116.16
(N–H stretch), 3014.18 (Ar C–H stretch), 2912.64 (C–H
stretch), 1545.45 (Ar C‚C stretch); 1H NMR (DMSO-d6):
8.59 (s, 2H, NH2), 6.70–7.51 (m, 7H, Ar-H), 5.42 (s, 2H,
NH2), 5.07 (s, 2H, OCH2), 3.95 (d, 2H, CH2), 3.84 (s, 3H,
OCH3), 3.50 (s, 1H, CH); MS (m/z %): 485.10 [M
+].
5.3.6. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carbothioamide (6f)
Yield 42%; mp: 268–272 C; IR (KBr, cm1): 3187.53, 3157.32
(N–H stretch), 3027.35 (Ar C–H stretch), 2995.45 (C–H
stretch), 1562.80 (Ar C‚C stretch); 1H NMR (DMSO-d6):
9.24 (s, 2H, NH2), 7.24–8.22 (m, 7H, Ar-H), 5.89 (s, 2H,
NH2), 5.29 (s, 2H, OCH2), 4.14 (d, 2H, CH2), 3.82 (s, 6H,
OCH3), 3.68 (s, 1H, CH); MS (m/z %): 471.08 [M+1]
+.
5.3.7. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(4-ﬂuorophenyl)-4,5-dihydro-1H-pyrazole-
1-carbothioamide (6g)
Yield 20%; mp: 244–247 C; IR (KBr, cm1): 3363.09, 3352.25
(N–H stretch), 3130.92 (Ar C–H stretch), 2969.22 (C–H
stretch), 1593.69 (Ar C‚C stretch); 1H NMR (DMSO-d6):
9.48 (s, 2H, NH2), 6.60–7.79 (m, 7H, Ar-H), 5.83 (s, 2H,
NH2), 5.27 (s, 2H, OCH2), 4.30 (d, 2H, CH2), 3.84 (s, 3H,
OCH3), 3.56 (s, 1H, CH); MS (m/z %): 458.12 [M
+].
5.3.8. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole-1-
carbothioamide (6h)
Yield 44%; mp: 302–306 C; IR (KBr, cm1): 3299.55, 3257.54
(N–H stretch), 3051.18 (Ar C–H stretch), 2992.21 (C–H
stretch), 1590.21 (Ar C‚C stretch); 1H NMR (DMSO-d6):
8.28 (s, 2H, NH2), 6.69–7.94 (m, 7H, Ar-H), 5.83 (s, 2H,
NH2). 5.27 (s, 2H, OCH2), 4.24 (d, 2H, CH2), 3.84 (s, 3H,
OCH3), 3.67 (s, 1H, CH); MS (m/z %): 485.04 [M
+].
5.3.9. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(4-bromophenyl)-4,5-dihydro-1H-pyrazole-
1-carbothioamide (6i)
Yield 66%; mp: 274–279 C; IR (KBr, cm1): 3186.70, 3157.40
(N–H stretch), 3025.65 (Ar C–H stretch), 2963.90 (C–H
stretch), 1570.29 (Ar C = C stretch); 1H NMR (DMSO-d6):
9.26 (s, 2H, NH2), 6.69–8.32 (m, 7H, Ar-H), 5.67 (s, 2H,
NH2), 5.27 (s, 2H, OCH2), 4.27 (d, 2H, CH2), 3.86 (s, 3H,
OCH3), 3.56 (s, 1H, CH); MS (m/z %): 518.08 [M
+], 519.01
[M+1]+.
5.3.10. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazole-1-
carbothioamide (6j)
Yield 62%; mp: 282–286 C; IR (KBr, cm1): 3195.20, 3169.97
(N–H stretch), 3063.47 (Ar C–H stretch), 2956.65 (CH3
stretch), 1585.97 (Ar C‚C stretch); 1H NMR (DMSO-d6):
8.59 (s, 2H, NH2), 6.72–7.94 (m, 7H, Ar-H), 5.48 (s, 2H,
NH2), 5.12 (s, 2H, OCH2), 4.08 (d, 2H, CH2), 3.84 (s, 3H,OCH3), 3.41 (s, 1H, CH), 2.55 (s, 3H, CH3); MS (m/z %):
454.21 [M+].
5.3.11. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(3-hydroxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carbothioamide (6k)
Yield 66%; mp: 312–317 C; IR (KBr, cm1): 3612.26 (O–H
stretch), 3166.10, 3152.56 (N–H stretch), 3020.71 (Ar C–H
stretch), 2998.16 (C–H stretch), 1594.25(Ar C‚C stretch);
1H NMR (DMSO-d6): 10.71 (s, 1H, OH), 9.97 (s, 2H, NH2),
7.61–8.41 (m, 7H, Ar-H), 5.48 (s, 2H, NH2), 4.02 (s, 2H,
OCH2), 4.05 (d, 2H, CH2), 3.80 (s, 3H, OCH3), 3.50 (s, 1H,
CH); MS (m/z %): 456.14 [M+].
5.3.12. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(2-hydroxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carbothioamide (6l)
Yield 68%; mp: 258–262 C; IR (KBr, cm1): 3626.26 (O–H
stretch), 3157.20, 3145.56 (N–H stretch), 3059.21 (Ar C–H
stretch), 2967.66 (C–H stretch), 1568.35 (Ar C‚C stretch);
1H NMR (DMSO-d6): 10.24 (s, 1H, OH), 9.53 (s, 2H, NH2),
7.82–8.66 (m, 7H, Ar-H), 5.50 (s, 2H, NH2), 4.46 (s, 2H,
OCH2), 4.35 (d, 2H, CH2), 3.84 (s, 3H, OCH3), 3.32 (s, 1H,
CH); MS (m/z %): 456.09 [M+].
5.3.13. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole-
1-carbothioamide (6m)
Yield 65%; mp: 228–232 C; IR (KBr, cm1): 3134.40, 3167.96
(N–H stretch), 3040.85 (Ar C–H stretch), 2967.07 (C–H
stretch), 1559.59 (Ar C‚C stretch); 1H NMR (DMSO-d6):
9.32 (s, 2H, NH2), 7.34–8.24 (m, 7H, Ar-H), 5.26 (s, 2H,
NH2), 4.35 (s, 2H, OCH2), 4.03 (d, 2H, CH2), 3.86 (s, 3H,
OCH3), 3.20 (s, 1H, CH); MS (m/z %): 475.02 [M+1]
+.
5.3.14. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(2-aminophenyl)-4,5-dihydro-1H-pyrazole-
1-carbothioamide (6n)
Yield 59%; mp: 264–268 C; IR (KBr, cm1): IR (KBr, cm1):
3283.34, 3270.08 (N–H stretch), 3027.16 (Ar C–H stretch),
2976.08 (C–H stretch), 1578.93 (Ar C‚C stretch); 1H NMR
(DMSO-d6): 11.3 (s, 2H, NH2), 10.8 (s, 2H, NH2), 6.74–8.41
(m, 7H, Ar-H), 5.76 (s, 2H, NH2), 5.36 (s, 2H, OCH2), 4.20
(d, 2H, CH2), 3.87 (s, 3H, OCH3), 3.24 (s, 1H, CH); MS (m/
z %): 455.19 [M+].
5.3.15. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(2,4-dihydroxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carbothioamide (6o)
Yield 67%; mp: 306–310 C; IR (KBr, cm1): 3662.26 (O–H
stretch), 3156.50, 3146.76 (N–H stretch), 3020.71 (Ar C–H
stretch), 2978.76 (C–H stretch), 1598.95 (Ar C‚C stretch);
1H NMR (DMSO-d6): 11.01 (s, 1H, OH), 10.35 (s, 1H, OH),
9.78 (s, 2H, NH2), 7.78–8.45 (m, 7H, Ar-H), 5.67 (s, 2H,
NH2), 4.37 (s, 2H, OCH2), 4.10 (d, 2H, CH2), 3.87 (s, 3H,
OCH3), 3.08 (s, 1H, CH); MS (m/z %): 472.22 [M
+].
5.3.16. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(4-aminophenyl)-4,5-dihydro-1H-pyrazole-
1-carbothioamide (6p)
Yield 70%; mp: 222–226 C; IR (KBr, cm1): 3157.80, 3146.06
(N–H stretch), 3056.51 (Ar C–H stretch), 2989.61 (C–H
S1288 M.N. Noolvi et al.stretch), 1549.52 (Ar C‚C stretch); 1H NMR (DMSO-d6):
10.2 (s, 2H, NH2), 9.87 (s, 2H, NH2), 7.98–8.89 (m, 7H, Ar-
H), 5.87 (s, 2H, NH2), 4.67 (s, 2H, OCH2), 4.31 (d, 2H,
CH2), 3.83 (s, 3H, OCH3), 3.56 (s, 1H, CH); MS (m/z %):
455.22 [M+].
5.3.17. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazole-
1-carbothioamide (6q)
Yield 65%; mp: 254–258 C; IR (KBr, cm1): 3189.20, 3179.36
(N–H stretch), 3067.17 (Ar C–H stretch), 2978.87 (C–H
stretch), 1578.52 (Ar C‚C stretch); 1H NMR (DMSO-d6):
8.98 (s, 2H, NH2), 7.21–8.81 (m, 7H, Ar-H), 5.87 (s, 2H,
NH2), 4.85 (s, 2H, OCH2), 4.29 (d, 2H, CH2), 3.83 (s, 3H,
OCH3), 3.78 (s, 1H, CH); MS (m/z %): 475.23 [M+1]
+.
5.3.18. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-(4-hydroxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carbothioamide (6r)
Yield 69%; mp: 288–292 C; IR (KBr, cm1): 3645.54 (O–H
stretch), 3177.10, 3168.06 (N–H stretch), 3045.91 (Ar C–H
stretch), 2930.09 (C–H stretch), 1578.76 (Ar C‚C stretch);
1H NMR (DMSO-d6): 10.98 (s, 1H, OH), 9.87 (s, 2H, NH2),
7.89–8.78 (m, 7H, Ar-H), 5.89 (s, 2H, NH2), 4.87 (s, 2H,
OCH2), 4.60 (d, 2H, CH2), 3.80 (s, 3H, OCH3), 3.64 (s, 1H,
CH); MS (m/z %): 456.14 [M+].
5.3.19. 3-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)-3-
methoxyphenyl)-5-m-tolyl-4,5-dihydro-1H-pyrazole-1-
carbothioamide (6s)
Yield 64%; mp: 272–276 C; IR (KBr, cm1): 3167.90, 3187.16
(N–H stretch), 3034.91 (ArC–H stretch), 2999.16 (C–H stretch),
1580.75 (Ar C‚C stretch); 1H NMR (DMSO-d6): 8.97 (s, 2H,
NH2), 7.91–8.71 (m, 7H, Ar-H), 5.49 (s, 2H, NH2), 4.30 (s,
2H, OCH2), 4.16 (d, 2H, CH2), 3.89 (s, 3H, OCH3), 3.02 (s,
1H, CH), 2.67 (s, 3H, CH3); MS (m/z%): 454.02 [M
+].
6. Conclusion
A total of 19 compoundswere synthesized and screened for their
antibacterial activity against S. aureus, S. enterica,
V. cholera, B. subtilis, P. mirabili, E. coli V517,M. smegmatics,
P. aeruginosa and antifungal activity againstC. albicans. The%
inhibition of all the compounds was determined by observing
the zones of inhibition formed around the cup after 24 h of incu-
bation for antibacterial and 48 h for antifungal activities.
Among the tested compounds 6h, 6e, 6k, 6o, 6p and 6h, 6e pos-
sess signiﬁcant antibacterial and antifungal activities, respec-
tively while rest of all the 1,3,4-thiadiazole derivatives showed
moderate antimicrobial activity as compared to standards.Acknowledgment
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